Let-7b expression determines response to chemotherapy through the regulation of Cyclin D1 in Glioblastoma

Journal of Experimental and Clinical Cancer Research

Volumn 32, Issue 1, 2013, Pages

  Guo, Yong ^a   Yan, Kuipo ^b   Fang, Jiasheng ^a   Qu, Qiang ^c   Zhou, Ming ^c   Chen, Fenghua ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF HENAN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^c CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Cisplatin; Cyclin D1; Drug resistance; Glioblastoma; Let 7b

Indexed keywords

CISPLATIN; CYCLIN D1; MICRORNA; MICRORNA LET 7B; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BIOINFORMATICS; CANCER PROGNOSIS; CANCER RESISTANCE; CELL CYCLE REGULATION; CONTROLLED STUDY; DRUG RESPONSE; FLUORESCENCE ACTIVATED CELL SORTING; GLIOBLASTOMA; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BRAIN NEOPLASMS; CELL LINE, TUMOR; CISPLATIN; CYCLIN D1; DRUG RESISTANCE, NEOPLASM; G1 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GLIOBLASTOMA; HUMANS; MICRORNAS; TRANSFECTION;

EID: 84879457821     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-32-41     Document Type: Article

References (43)

1. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Furnari FB, Fenton T, Bachoo RM, et al. Genes Dev 2007 21 2683 2710 10.1101/gad.1596707 17974913
2. Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991. Davis FG, Freels S, Grutsch J, et al. J Neurosurg 1998 88 1 10 10.3171/jns.1998.88.1.0001 9420066
3. The transcriptional network for mesenchymal transformation of brain tumours. Carro MS, Lim WK, Alvarez MJ, et al. Nature 2010 463 318 325 10.1038/nature08712 20032975
4. Primary brain tumours in adults. Behin A, Hoang-Xuan K, Carpentier AF, et al. Lancet 2003 361 323 331 10.1016/S0140-6736(03)12328-8 12559880
5. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. Stupp R, Mason WP, van den Bent MJ, et al. N Engl J Med 2005 352 987 996 10.1056/NEJMoa043330 15758009
6. MicroRNAs: genomics, biogenesis, mechanism, and function. Bartel DP, Cell 2004 116 281 297 10.1016/S0092-8674(04)00045-5 14744438
7. microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Zhao JJ, Lin J, Lwin T, Blood 2010 115 2630 2639 10.1182/blood-2009-09-243147 20086245
8. MicroRNA signatures in human cancers. Calin GA, Croce CM, Nat Rev Cancer 2006 6 857 866 10.1038/nrc1997 17060945
9. MicroRNA involvement in glioblastoma pathogenesis. Novakova J, Slaby O, Vyzula R, et al. Biochem Biophys Res Commun 2009 386 1 5 10.1016/j.bbrc.2009.06. 034 19523920
10. Role of microRNAs in gliomagenesis: targeting miRNAs in glioblastoma multiforme therapy. Nikaki A, Piperi C, Papavassiliou AG, Expert Opin Investig Drugs 2012 21 1475 1488 10.1517/13543784.2012.710199 22809292
11. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Chan JA, Krichevsky AM, Kosik KS, Cancer Res 2005 65 6029 6033 10.1158/0008-5472.CAN- 05-0137 16024602
12. MicroRNA gene expression deregulation in human breast cancer. Iorio MV, Ferracin M, Liu CG, et al. Cancer Res 2005 65 7065 7070 10.1158/0008-5472.CAN- 05-1783 16103053
13. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Takamizawa J, Konishi H, Yanagisawa K, et al. Cancer Res 2004 64 3753 3756 10.1158/0008-5472.CAN-04-0637 15172979
14. Alterations of microRNAs contribute to colon carcinogenesis. Schetter AJ, Harris CC, Semin Oncol 2011 38 734 742 10.1053/j.seminoncol.2011.08.009 22082759
15. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Yang H, Kong W, He L, et al. Cancer Res 2008 68 425 433 10.1158/0008-5472.CAN-07-2488 18199536
16. Drug resistance in glioblastoma: a mini review. Haar CP, Hebbar P, Wallace GC, Neurochem Res 2012 37 1192 1200 10.1007/s11064-011-0701-1 22228201
17. The resurgence of platinum-based cancer chemotherapy. Kelland L, Nat Rev Cancer 2007 7 573 584 10.1038/nrc2167 17625587
18. Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients. Silvani A, Eoli M, Salmaggi A, et al. J Neurooncol 2004 66 203 208 15015788
19. Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North Central Cancer Treatment Group 93-72-52 and Southwest Oncology Group 9503 Trials. Buckner JC, Ballman KV, Michalak JC, et al. J Clin Oncol 2006 24 3871 3879 10.1200/JCO.2005.04.6979 16921039
20. A phase I study of cisplatin, temozolomide and thalidomide in patients with malignant brain tumors. Zustovich F, Cartei G, Ceravolo R, et al. Anticancer Res 2007 27 1019 1024 17465237
21. A phase II study of cisplatin and temozolomide in heavily pre-treated patients with temozolomide-refractory high-grade malignant glioma. Zustovich F, Lombardi G, Della Puppa A, et al. Anticancer Res 2009 29 4275 4279 19846986
22. First-line chemotherapy with cisplatin plus fractionated temozolomide in recurrent glioblastoma multiforme: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia. Brandes AA, Basso U, Reni M, et al. J Clin Oncol 2004 22 1598 1604 10.1200/JCO.2004.11.019 15117981
23. Recent advances in management of patients with platinum-refractory testicular germ cell tumors. Kollmannsberger C, Nichols C, Bokemeyer C, Cancer 2006 106 1217 1226 10.1002/cncr.21742 16463389
24. How do real tumors become resistant to cisplatin? Borst P, Rottenberg S, Jonkers J, Cell Cycle 2008 7 1353 1359 10.4161/cc.7.10.5930 18418074
25. Towards an understanding of the biological basis of response to cisplatin-based chemotherapy in germ-cell tumors. Mayer F, Honecker F, Looijenga LH, et al. Ann Oncol 2003 14 825 832 10.1093/annonc/mdg242 12796018
26. Casein kinase 1alpha regulates an MDMX intramolecular interaction to stimulate p53 binding. Wu S, Chen L, Becker A, et al. Mol Cell Biol 2012 32 4821 4832 10.1128/MCB.00851-12 23028042
27. The downregulation of onzin expression by PKCepsilon-ERK2 signaling and its potential role in AML cell differentiation. Wu SF, Huang Y, Hou JK, et al. Leukemia 2010 24 544 551 10.1038/leu.2009.280 20072156
28. Hypoxia-inducible factor-1alpha-induced differentiation of myeloid leukemic cells is its transcriptional activity independent. Song LP, Zhang J, Wu SF, et al. Oncogene 2008 27 519 527 10.1038/sj.onc.1210670 17637739
29. Intrinsic and acquired drug resistance in malignant tumors. The main reason for therapeutic failure. Lippert TH, Ruoff HJ, Volm M, Arzneimittelforschung 2008 58 261 264 18677966
30. Drug resistance in cancer: a perspective. Goldie JH, Cancer Metastasis Rev 2001 20 63 68 10.1023/A:1013164609041 11831649
31. MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity. Shi L, Chen J, Yang J, et al. Brain Res 2010 1352 255 264 20633539
32. MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in glioblastoma multiforme. Li Y, Li W, Yang Y, et al. Brain Res 2009 1286 13 18 19559015
33. miR-195, miR-455-3p and miR-10a(*) are implicated in acquired temozolomide resistance in glioblastoma multiforme cells. Ujifuku K, Mitsutake N, Takakura S, et al. Cancer Lett 2010 296 241 248 10.1016/j.canlet.2010.04.013 20444541
34. Differential processing of let-7a precursors influences RRM2 expression and chemosensitivity in pancreatic cancer: role of LIN-28 and SET oncoprotein. Bhutia YD, Hung SW, Krentz M, et al. PLoS One 2013 8 53436 10.1371/journal.pone. 0053436 23335963
35. MicroRNA let-7a represses chemoresistance and tumourigenicity in head and neck cancer via stem-like properties ablation. Yu CC, Chen YW, Chiou GY, et al. Oral Oncol 2011 47 202 210 10.1016/j.oraloncology.2010.12.001 21292542
36. Let-7 expression is a significant determinant of response to chemotherapy through the regulation of IL-6/STAT3 pathway in esophageal squamous cell carcinoma. Sugimura K, Miyata H, Tanaka K, et al. Clin Cancer Res 2012 18 5144 5153 10.1158/1078-0432.CCR-12-0701 22847808
37. MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth. Schultz J, Lorenz P, Gross G, et al. Cell Res 2008 18 549 557 10.1038/cr.2008.45 18379589
38. Effects of let-7 microRNA on Cell Growth and Differentiation of Papillary Thyroid Cancer. Ricarte-Filho JC, Fuziwara CS, Yamashita AS, et al. Transl Oncol 2009 2 236 241 19956384
39. MicroRNA let-7b regulates neural stem cell proliferation and differentiation by targeting nuclear receptor TLX signaling. Zhao C, Sun G, Li S, et al. Proc Natl Acad Sci U S A 2010 107 1876 1881 10.1073/pnas.0908750107 20133835
40. The association of cyclin D1 overexpression and cisplatin resistance in testicular germ cell tumors and other cancers. Noel EE, Yeste-Velasco M, Mao X, et al. Am J Pathol 2010 176 2607 2615 10.2353/ajpath.2010.090780 20395447
41. Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumor cell line. Biliran H Jr, Wang Y, Banerjee S, et al. Clin Cancer Res 2005 11 6075 6086 10.1158/1078-0432.CCR-04-2419 16115953
42. Inhibition of basal and mitogen-stimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum. Kornmann M, Arber N, Korc M, J Clin Invest 1998 101 344 352 10.1172/JCI1323 9435306
43. Inhibition of cyclin D1 expression in human pancreatic cancer cells is associated with increased chemosensitivity and decreased expression of multiple chemoresistance genes. Kornmann M, Danenberg KD, Arber N, et al. Cancer Res 1999 59 3505 3511 10416617